NAD+ in cognitive function and neuroprotection

The research community has spent a considerable amount of effort trying to understand what's happening at the cellular level when cognitive function changes with age. One thread that's been running through the neuroscience and aging literature for the past two decades involves NAD+ — not because it's the only factor, or even necessarily the primary one, but because it sits at the intersection of several processes that are each known to matter for neuronal health: energy metabolism, inflammation control, DNA repair, and the regulation of proteins that govern whether neurons thrive or degrade.

The brain is metabolically expensive. It's roughly 2 percent of body weight and accounts for 20 percent of resting energy expenditure. Neurons are continuously active — they're firing, maintaining electrochemical gradients, releasing and recycling neurotransmitters, pruning and strengthening synaptic connections — and all of this requires ATP at a rate that makes neuronal mitochondria among the most heavily worked in the body. NAD+ is a rate-limiting cofactor in the mitochondrial electron transport chain — specifically in the NADH to NAD+ cycling that drives ATP production — which means that in a tissue with very high and continuous energy demands, NAD+ availability directly affects how well the engine runs. A neuron with depleted NAD+ is not going to meet its energy requirements as efficiently, and that inefficiency compounds in a tissue that doesn't replace itself easily.

The sirtuin angle is where the story gets more specific. Sirtuins are a family of NAD+-dependent deacetylases — proteins that remove acetyl groups from other proteins and in doing so regulate their function. SIRT1, SIRT3, and SIRT6 are the three most relevant to neuronal health, and their dependence on NAD+ is not metaphorical: they require NAD+ as a cosubstrate to perform their deacetylase activity. When NAD+ is abundant, sirtuins are active. When NAD+ declines, sirtuin activity declines proportionally.

In the brain, SIRT1 is particularly well-studied. It regulates several processes that bear directly on cognitive function and neurodegeneration. It modulates the expression of BDNF — brain-derived neurotrophic factor, the protein that supports the survival and growth of neurons and is essential for synaptic plasticity. SIRT1 also influences the processing of amyloid precursor protein in ways that have relevance to Alzheimer's pathology, and it suppresses NF-κB, a master regulator of inflammatory signaling. When SIRT1 activity drops — as it does when NAD+ declines — BDNF expression can fall, inflammatory signaling can rise, and the cellular environment in neurons shifts in directions associated with degradation rather than maintenance.

SIRT3 is the primary sirtuin in the mitochondrial matrix and is central to mitochondrial function. It deacetylates and activates enzymes involved in the electron transport chain and in oxidative stress defense. SIRT3 deficiency in animal models produces elevated mitochondrial reactive oxygen species and neuronal dysfunction; restoring SIRT3 activity, including through NAD+ precursor supplementation, attenuates these effects in preclinical research.

SIRT6 regulates DNA repair and genomic stability, which matters increasingly in aged neurons because DNA damage accumulates with time and the repair mechanisms that should address it require both functional SIRT6 and adequate NAD+. Neurons are post-mitotic — they generally can't replace themselves when they die — which makes DNA repair even more critical to maintaining functional neurons in an aging brain than it would be in a tissue with higher turnover.

The neurodegeneration research deserves careful handling, because the distance between preclinical results and human outcomes is particularly long in this field. In Alzheimer's disease models — particularly APP/PS1 and 5xFAD transgenic mouse models — NR and NMN supplementation has produced improvements in cognitive performance, reduction in amyloid burden, and improvements in synaptic density. The mechanisms proposed include SIRT1-mediated modulation of amyloid precursor protein processing (shifting it toward non-amyloidogenic pathways), PARP inhibition reducing neuroinflammation, and mitochondrial function improvement through SIRT3. These are biologically coherent results and they've been replicated in multiple labs.

In Parkinson's disease models, NAD+ precursor supplementation has shown neuroprotective effects in dopaminergic neurons in the substantia nigra, and the SIRT3 pathway is implicated in protecting mitochondrial function in those neurons against the kinds of oxidative stress and complex I impairment associated with Parkinson's pathology.

The translation to human neurodegenerative disease is where the evidence gets thin. There are no large controlled human trials establishing that NAD+ supplementation slows Alzheimer's or Parkinson's progression. There are observational studies, pilot studies, and a growing clinical trial landscape — several trials of NR and NMN in early Alzheimer's and mild cognitive impairment are ongoing — but robust clinical outcomes data in humans does not yet exist. This is not a reason to dismiss the preclinical work, which is unusually mechanistically coherent for this area of research. It is a reason to be honest about what we know and don't know.

In normal aging cognitive decline — the subtle fogginess, the slower processing, the word-retrieval latency — the evidence for NAD+ support is similarly preclinical-heavy. Some human trials with NR or NMN have included cognitive endpoints or quality of life measures, and some have shown modest improvements in subjective and objective cognitive metrics. The sample sizes are small, the measurement tools vary, and the effect sizes are not dramatic. What is consistent is that the direction of effect, where it's observed, is the direction the mechanism predicts.

The mood and depression angle is worth spending a moment on. SIRT1's regulation of BDNF is relevant not just to memory and cognition but to mood. BDNF has a well-established role in depression — the BDNF hypothesis of depression holds that reduced BDNF expression in the hippocampus and prefrontal cortex contributes to depressive pathology, and several antidepressant mechanisms, including exercise and some pharmacological treatments, appear to work partly through BDNF restoration. The sirtuin-BDNF pathway, in which declining NAD+ reduces SIRT1 activity which reduces BDNF expression, connects NAD+ to mood regulation through a pathway that's mechanistically credible. Human trial data specifically on mood and depression endpoints for NAD+ precursors is limited, but the biological plausibility is real.

There is also a direct mitochondrial angle that doesn't require the sirtuin pathway. Neurons in the prefrontal cortex — the region most associated with executive function, working memory, and the kind of higher-order processing that tends to feel cognitively sharp — have very high mitochondrial density relative to other brain regions. They need it. The same NAD+-dependent mitochondrial energy production that matters everywhere in the body matters particularly in regions where the cognitive work you care about is actually happening. Mitochondrial dysfunction in prefrontal neurons is associated with cognitive impairment in animal models and increasingly studied in human neurodegenerative conditions.

PARP activity is another connection point. In neurons experiencing DNA damage — which accumulates with age and with exposure to oxidative stress — PARP enzymes consume NAD+ rapidly to execute repair. This PARP-mediated NAD+ depletion has been studied specifically in the context of neuronal survival after injury and in the context of neurodegeneration: excessive PARP activation can actually drive cell death by depleting NAD+ to the point where the cell can't maintain its energy metabolism, a process called parthanatos. At lower levels, chronic PARP activation consuming NAD+ in response to cumulative DNA damage may contribute to the NAD+ deficit that impairs the sirtuin and mitochondrial pathways described above.

Where does NAD+ fit alongside other cognitive support interventions? Honestly, it's probably not a standalone intervention and the evidence doesn't position it as one. The cognitive benefits that NAD+ supplementation might help support — particularly through the mitochondrial and sirtuin pathways — are likely to be more meaningful when the foundational lifestyle factors are in place: adequate sleep (during which memory consolidation and BDNF expression occur), regular aerobic exercise (which raises BDNF more reliably than any supplement), stress management (chronic stress is one of the most consistent suppressors of prefrontal function and BDNF), and a nutritional approach that supports mitochondrial health. NAD+ support in that context may add something real. As a substitute for those fundamentals, it adds less.

The picture that emerges from the research is of a molecule that's genuinely important for the cellular machinery of cognition — energy production, sirtuin regulation, DNA repair — whose age-related decline matters in neurons in ways that are mechanistically plausible and preclinically demonstrated, and whose restoration through supplementation produces measurable but modest effects in human cognitive endpoints in the trials that have measured them. That's an honest summary, and it leaves room for the possibility that larger and longer trials, better targeted to populations with meaningful NAD+ deficits, will show more. What it doesn't support is the stronger version of the claim — that NAD+ supplementation reliably prevents cognitive aging or treats neurodegenerative disease. The cellular mechanisms are well-supported. The clinical outcomes remain to be established.